IDH1 and glioblastoma: In terms of survival analysis, a longer PFS was observed in GBM patients with low BCAT1 expression than those with high expression, regardless of the IDH1 mutation status, while there was no significant difference in PFS according to the MGMT promoter methylation status in patients with IDH1-wildtype GBMs.